Ubs Group Ag Arcellx, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Arcellx, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 57,363 shares of ACLX stock, worth $4.77 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

57,363

Previous 63,577 9.77%

Holding current value

$4.77 Million

Previous $3.51 Million 36.55%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$50.91 - $86.61 $316,354 - $538,194	-6,214 Reduced 9.77%	57,363 $4.79 Million
Q2 2024 Aug 13, 2024	SELL	$49.74 - $66.98 $1.98 Million - $2.67 Million	-39,904 Reduced 38.56%	63,577 $3.51 Million
Q1 2024 May 13, 2024	BUY	$51.85 - $73.49 $333,706 - $472,981	6,436 Added 6.63%	103,481 $7.2 Million
Q4 2023 Feb 09, 2024	BUY	$31.75 - $57.99 $1.51 Million - $2.76 Million	47,613 Added 96.32%	97,045 $5.39 Million
Q3 2023 Nov 09, 2023	SELL	$31.51 - $37.4 $2.27 Million - $2.7 Million	-72,075 Reduced 59.32%	49,432 $1.77 Million
Q2 2023 Aug 11, 2023	BUY	$27.49 - $46.9 $3.31 Million - $5.65 Million	120,515 Added 12148.69%	121,507 $3.84 Million
Q1 2023 May 12, 2023	SELL	$26.92 - $33.94 $39,007 - $49,179	-1,449 Reduced 59.36%	992 $30,000
Q4 2022 Feb 08, 2023	SELL	$17.18 - $33.0 $3.17 Million - $6.08 Million	-184,236 Reduced 98.69%	2,441 $75,000
Q3 2022 Nov 10, 2022	SELL	$16.67 - $22.04 $166,366 - $219,959	-9,980 Reduced 5.07%	186,677 $3.5 Million
Q2 2022 Aug 10, 2022	SELL	$7.21 - $24.43 $213,444 - $723,225	-29,604 Reduced 13.08%	196,657 $3.56 Million
Q1 2022 May 16, 2022	BUY	$12.97 - $19.14 $2.93 Million - $4.33 Million	226,261 New	226,261 $3.17 Million

Others Institutions Holding ACLX

# of Institutions

205

Shares Held

44.2M

Call Options Held

2.23M

Put Options Held

907K

View Full List

About Arcellx, Inc.

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $3.64B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

More about ACLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account